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Abstract
Access to quality assured artemisinin-based combination therapy (ACT) has remained very low in most malaria
endemic countries. A number of reasons, including unaffordable prices, have contributed to the low accessibility to
these life-saving medicines. The Affordable Medicines Facility-Malaria (AMFm) is a mechanism to increase access to
quality assured ACT. The AMFm will use price signals and a combination of public and private sector channels to
achieve multiple public health objectives: replacing older and increasingly ineffective anti-malarial medicines, such
as chloroquine and sulphadoxine-pyrimethamine with ACT, displacing oral artemisinin monotherapies from the
market, and prolonging the lifespan of ACT by reducing the likelihood of resistance to artemisinin.
Access to medicines frameworks paint a broad picture of dimensions of access to medicines and juxtapose
components that enhance or hinder access to medicines. Access requires various activities–funding, institutions,
interventions, and thinking–from public and private actors at global, national, and local levels. This paper examines,
within access to medicines frameworks, the role of the AMFm across and within each dimension and discusses
how the AMFm can help to solve access bottlenecks.
Background
Universal access to effective malaria treatment is among
the United Nations’ Millennium Development Goals [1].
This also is among the goals of the Roll Back Malaria
Partnership [2]. In spite of high-level commitments,
political will and substantial increases in financing, the
attainment of this goal has remained elusive in most
malaria-endemic countries [3], especially in relation to
artemisinin-based combination therapy (ACT), the treat-
ment recommended as first-line by the World Health
Organization (WHO) for uncomplicated malaria caused
by Plasmodium falciparum [4].
In the World Malaria Report 2009 [3], WHO reported
that access to ACT was generally poor in African coun-
tries, with less than 15 percent of children under five
years of age receiving an ACT when they had fever in
11 of 13 African countries for which survey data were
available. These findings are consistent with results of
more recent multi-country surveys[5], which included
findings for the Democratic Republic of Congo and
Nigeria, the largest countries with regard to malaria bur-
den and which together account for approximately 36
percent of all estimated malaria cases in the WHO
Africa Region [3].
The Affordable Medicines Facility-malaria (AMFm) is
a new financing mechanism to expand access to effec-
tive malaria treatment [6-8]. A response to the dual
challenge of poor access to quality-assured anti-malarial
medicines and threats of parasite resistance to treatment
[6], the AMFm combines price negotiations with a fac-
tory-gate buyer subsidy to reduce the price of ACT. The
AMFm will use price signals and a combination of pub-
lic and private sector channels to achieve multiple pub-
lic health objectives. These objectives include replacing
older and increasingly ineffective anti-malarial medi-
cines, such as chloroquine and sulphadoxine-pyrimetha-
mine with ACT, displacing oral artemisinin
monotherapies from the market, and prolonging the life-
span of ACT by reducing the likelihood of resistance to
artemisinin [4].
T h eA M F mi sh o s t e db yt h eG l o b a lF u n dt oF i g h t
AIDS, Tuberculosis and Malaria. The pilot phase of the
programme, which includes Cambodia, Ghana, Kenya,
Madagascar, Niger, Nigeria, the United Republic of Tan-
zania and Uganda, is scheduled to last from 2010 to
2012. The AMFm is funded from multiple sources
including a co-payment fund of US$216 million,
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UK Government, and UNITAID. In addition, the Global
Fund provides US$127 million to fund supporting inter-
ventions at the country level. Using established access to
medicines frameworks [9-11], this paper examines how
the AMFm can improve access to effective malaria treat-
ment in malaria endemic countries.
Access to medicines
In May 2008, WHO adopted the global strategy and
plan of action on public health, innovation and intellec-
tual property [12]. This strategy includes a focus on
improving the delivery of and access to medicines by
effectively implementing successful interventions.
Often, interventions to improve access to medicines
focus on the ability to acquire and to utilize medicines
alone. Yet access to prompt and effective treatment is
broader than the ability to acquire medicines or to uti-
lize services. Access to medicines frameworks paint a
broad picture of dimensions of access to medicines and
juxtapose components that enhance or hinder access to
medicines. Most access to medicines frameworks break
down access into four main domains; geographical
accessibility, availability, affordability and acceptability
[9,10]. A more analytical framework by Frost and Reich
[11] adds an organizational dimension, architecture, to a
supply component. The architecture is a dimension that
allows for coordination of the other access components.
This paper adopts Frost and Reich’s definition of access
as “people’s ability to obtain and appropriately use good
quality health technologies when they are needed” [11].
The Frost and Reich framework adds further value to
access frameworks by mapping the specific activities
required to enhance access from the global level down
to the user level.
Access requires various activities–funding, institutions,
interventions, and analyses–from public and private
actors at global, national, and local levels. Within access
to medicines frameworks this paper examines the role
of the AMFm across and within each access dimension
(Table 1). Furthermore, the paper analyses and discusses
how the AMFm can help to resolve access bottlenecks
within each dimension. A major limitation of this analy-
s i si st h a tt h eA M F mi sp r i m arily an architecture for
financing commodities and as such does not satisfy all
the dimensions of access to medicines. The conclusions,
therefore, should be considered in this context.
Architecture (Table 1)
Providing access requires work by many different indivi-
duals and organizations. Architecture refers to the
design and structure of a network of executors and
activities required to steer and connect the other access
streams (availability, affordability, and acceptability). The
AMFm is modeled to enhance access to inexpensive,
effective and quality-assured ACT. The model involves
the Global Fund, as host and manager of the AMFm,
negotiating with drug manufacturers to reduce the price
of ACT. In addition to negotiating price reductions, the
Global Fund pays a proportion of this reduced price (a
‘buyer co-payment’) directly to eligible manufacturers to
further lower the cost to eligible first-line buyers. First-
line buyers then pay the remainder of the sales price.
First-line buyers are encouraged to pass on the highest
possible proportion of this price benefit so that clients
are able to purchase ACT across the public, private not-
for-profit and for-profit sectors at a price competitive
with that of less-effective anti-malaria drugs, such as
chloroquine and sulphadoxine-pyrimethamine. The
AMFm has the potential to reduce the cost of ACT to
US$0.50 for most patients who pay for treatment. While
ACT prices are expected to trend sharply downwards
from current levels of up to US$6-10 per treatment, var-
iations are expected within and across countries.
Geographical accessibility
Geographic accessibility is a component of access that
refers to the supply of services location in relation to
user location. With regard to ACT, this domain refers
to the ease of accessing ACT in relation to the distance
to be travelled, the mode of transport for the user and
the time it takes to reach the service delivery point. In
most developing countries, the distance from health
facilities is a critical factor influencing the use of formal
Table 1 Dimensions of access
Dimension Definition Attributes
Architecture Organizational structures and
relationships established with
the purpose of coordinating and
steering access related activities.
￿ Availability
￿ Affordability
￿ Geographical
accessibility
Geographic
accessibility
Defined by the relationship
between the location of the
product or service and the
location of the eventual user of
the product or service
￿ User’s location
￿ Location of drug
outlets
￿ Infrastructural
functionality e.g.
roads networks.
Physical
availability
Defined by the relationship
between the type and quantity
of product or service needed,
and the type and quantity of
product or service provided
￿ Medicines supply
￿ Medicines demand
￿ Supply chain
efficiency
Affordability Defined by the relationship
between prices of the products
or services and
the user’s ability to pay for them
￿ Price of medicines
￿ Price of services
￿ User’s income
Acceptability Defined by the relationship
between the user’s attitudes and
expectations about the products
and services and the
characteristics of products and
services
￿ Quality of products
￿ Quality of services
￿ User’s beliefs and
attitudes
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a reduction in the number of patients using formal
healthcare services as the distance from health facilities
increased [14], while a different study, also in Kenya,
reported that a third of patients who self-treated said
that they would have sought treatment from a health
facility if such a facility were near [15].
Related to distance is the question of how remote a
community is geographically. A number of studies in
malaria endemic areas have shown that most of the
approximately 900,000 annual malaria deaths occur in
young children in remote rural areas, which are often
hard to reach [16-18]. In many parts of Africa, the dis-
tribution of public healthcare facilities is uneven, with
the most remote parts, which often include the poorest
populations, being underserved [16].
Availability
Availability is defined as “obtainable or accessible and
ready for use” [19]. With regard to medicines, availabil-
ity refers to the physical presence of the medicine at
the service delivery point or the extent to which the
medicine can be obtained. Even when ACT is provided
free-of-charge in public, non-governmental and faith-
based healthcare facilities, availability in peripheral pub-
lic health facilities remains a challenge. In most
instances, ACT movement from the central medical
stores to the periphery is often irregular and inconsis-
tent. In 2008, a study in Kenya [20] showed that a quar-
ter of public health facilities had none of the nationally-
recommended ACT treatment in stock and three-
quarters lacked the full range of weight-specific packs
required.
The causes of stock-outs vary, but often reflect weak
drug management systems in disease-endemic countries.
Poorly resourced supply chains, weak stock management
practices, and inadequate lead-time planning can threa-
ten the regular availability of drugs in the public health
system. In addition, unpredictable flow of funds in many
countries, combined with inadequate distribution from
central warehouses to peripheral points of care, under-
mine the ability to ensure that ACT and other essential
drugs are always available at the last mile.
Affordability
Affordability refers to the price of commodities or ser-
vices in relation to the client’s ability to pay. In develop-
ing countries, most people who need medicines have to
pay for them out of their own pockets. Where the cost
of drugs is covered by formal health services, spending
on medicines is a major part of the total healthcare bud-
get. Unaffordable prices have been reported as the major
barrier to accessing ACT in malaria-endemic countries
[21,22]. Other things being equal, the retail prices of
medicines are determined by interplay of demand and
supply. As such, the AMFm aims to enhance access to
ACT by working through market forces to determine
the final sales price of quality-assured ACT on the mar-
ket. It also includes supporting interventions, such as
public information campaigns to mitigate the effects of
market failures, such as lack of information about ACT
[8].
Acceptability
Acceptability refers to the characteristics of products
and services in relation to user attitudes, perceptions or
expectations of products and services. Unlike the other
domains, acceptability is a qualitative domain. A variety
of interrelated socio-economic factors affect product
acceptability and hence prompt and effective access to
ACT and related medicines [23-26].
Acceptability is often affected by the community’s per-
ceptions of the quality of care provided at service deliv-
ery points, the community’st r u s ti nt h eh e a l t h c a r e
delivery system and their perception of the effectiveness
of specific interventions, including medicines. Related to
community perceptions of the quality of care are the
community’s perceptions of the cause of illness. In some
societies traditional beliefs can hinder prompt access to
effective treatment. For example, whereas convulsions
may be a sign of severe malaria, in some parts of Africa
they are associated with the supernatural [27-29], which
requires the use of traditional healers for its
management.
Communities’ perceptions of the effectiveness and det-
rimental effects of different types of treatment may hin-
der prompt access to the most effective treatment. In
some communities healthcare workers may continue to
prescribe non-recommended medicines because patients
demand it [30]. The above are challenges that cannot be
addressed by price reduction alone. Continuous educa-
tion about the safety and effectiveness of ACT should
be scaled-up together with the scale-up of ACT. The
AMFm will work with countries and technical partners
to scale-up social marketing interventions in malaria
endemic countries.
Enhancing access to quality-assured ACT
Even though ACT may be provided free-of-charge in
public and private-not-for profit facilities, the majority
of the populations in malaria endemic countries access
these life-saving medicines through the private sector,
where currently quality-assured ACT is seldom stocked.
Large public health facilities, even when they are easily
accessible geographically, tend to be overcrowded.
Therefore, in addition to the direct costs of services and
medicines, clients incur indirect costs in the form of tra-
vel and waiting time when they have to visit distant and
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ity of the population is within reach of a drug shop
[31-33]. The World Health Organization approximates
the total population that access healthcare services
through the private sector to be around 50% in the
WHO African and Western Pacific regions and up to
78% in the Southeast Asian region [34]. In Cambodia
this proportion is estimated to be as high as 90% [35].
In Tanzania and Burkina Faso, a clear majority of the
population obtains medicines for malaria through drug
shops [31,33,34]. Other conveniences, apart from acces-
sibility, add to the attractiveness of drug shops as the
first port of call. For instance, drug shops are often
open at hours convenient to the community, including
weekends and holidays, and in many instances they offer
medicines on loan to some of their clients. The private
sector, including drug shops, is, therefore, an important
target for enhancing access to quality-assured ACT
among different socio-economic groups.
Enabling appropriate and rational use of ACT
To preserve the effectiveness of ACT over time, it is
important that these life-saving medicines are used
appropriately. A number of studies have shown that
malaria case-management, particularly in the retail sec-
tor, is unsatisfactory [32,36]. The private sector, in parti-
cular drug outlets, should be supported and capacitated
to provide appropriate and rational management of
malaria. Integrated approaches aimed at improving
understanding and treatment of malaria can lead to tan-
gible improvements in management of malaria [37].
Building on lessons learned so far, the AMFm will work
with countries and technical partners to build the skills
of drug shop attendants using promising models, such
as the Tanzania Accredited Drugs Dispensing Outlets
(ADDOs)[36].
R e g u l a t i o nc a np l a ya ni m p o r t a n tr o l ei ne n h a n c i n g
access to ACT and improving the quality of care. A
number of studies have reported that subsidizing ACT
may need to be supported by effective regulatory poli-
cies for the intervention to be effective in crowding-out
less effective anti-malarials from the market [35,38].
Countries in AMFm Phase 1 may use funds from the
Global Fund to strengthen in-country regulatory
systems.
Related to regulation is product quality. The AMFm
will work with partners to adopt policies that assure
product quality. For instance, AMFm uses the Global
Fund’s quality assurance policy, which requires the pro-
curement of WHO-prequalified products and those that
have passed stringent quality assessment [39].
Product branding serves to establish bonds among
buyers, sellers and products. In many malaria-endemic
countries there are various products available for the
treatment of malaria. The availability of a wide range of
products can makes it harder for buyers to distinguish
quality-assured products from others. ACT under the
AMFm will bear a distinct logo that will serve as an
identifier and sales driver.
Finally, it is important to expand access to the parasi-
tological confirmation of malaria, with a view to ensur-
ing that only those who have malaria receive ACT as
treatment. Most cases of presumptive treatment with
ACT take place in the private sector. In the near-to
medium-term, it is highly unlikely that effective public
sector services will replace the private sector in most
malaria-endemic countries. Therefore, universal access
to diagnostics requires the achievement of universal
access to these technologies in the private sector. Given
the new WHO’s normative guideline on the goal of uni-
versal access to diagnostics [40], it is important to iden-
tify the most suitable financing mechanisms for
expanded access to diagnostics in the private sector, and
to better understand the most feasible ways of expand-
ing the use of diagnostics, particularly in the formal and
informal private sectors. The operations research ele-
ments of AMFm Phase 1 provide opportunities to learn
how to increase coverage of diagnostics in the private
sector in a way that can inform scaling up to universal
access.
Conclusion
Access to artemisinin combination therapy remains low
in most malaria endemic countries. A major impedi-
ment to access to these life-saving medicines is unaf-
fordable prices. The Affordable Medicines Facility-
malaria seeks to address the price barrier by drastically
reducing the price of ACT. In addition to unaffordable
prices, a variety of interrelated socio-economic factors
affect prompt and effective access to ACT. The distance
to facilities, locations of outlets and socio-economic sta-
tus are among the factors that can hinder access to
quality-assured ACT. The AMFm will support interven-
tions to address socio-economic barriers, strengthen
regulatory systems, improve supply chains and improve
quality of services as a means to improve access to life-
saving ACT.
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